PROPELLER
Research type
Research Study
Full title
PROPELLER: PROgressive lung fibrosis and 68Ga-FAPi-PET Longitudinal evaLuation for Early disease activity Readout
IRAS ID
347179
Contact name
Philip Molyneaux
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
3 years, 1 months, 31 days
Research summary
Pulmonary fibrosis or Interstitial Lung Disease (ILD) encompasses a wide spectrum of progressive and irreversible disorders destruction of the lung. Clinically this causes cough and progressive breathing difficulty. The commonest of these conditions, idiopathic pulmonary fibrosis (IPF), affects over 32 000 individuals in the UK and accounts for 1 in every 100 deaths in this country each year. Despite the recent approval of two antifibrotic drugs for IPF the 5-year survival rate remains 25%, far worse than many common cancers.
The diagnosis of IPF is frequently challenging requiring multiple tests including imaging, blood tests, lung function, bronchoscopy (camera test into the lungs) and sometimes a biopsy. This often leads to significant delays in diagnosis and treatment. To make matters worse following a diagnosis the clinical course of the disease is unpredictable with some patients surviving many years whilst others have an aggressive disease with rapid deterioration to death within 12 months.
Recently we have seen that in another ILD if we inject a radiolabeld dye it localized in the links and is able to predict people at risk of progressive disease. We hope to explore whether this is the same in people with IPF.
We hope this imaging may provide a non-invasive marker of disease activity. And that early signal changes in the lung of IPF patients may allow us to predict disease progression more accurately.
REC name
East of Scotland Research Ethics Service REC 1
REC reference
24/ES/0079
Date of REC Opinion
18 Nov 2024
REC opinion
Further Information Favourable Opinion